Mineralys Therapeutics, Inc. Common Stock Cash Flow-to-Debt Ratio
Mineralys Therapeutics, Inc. Common Stock cash flow-to-debt ratio. Mineralys Therapeutics, Inc. Common Stock (MLYS) has a Cash Flow-to-Debt Ratio of -0.28x as of June 2026, meaning its operating cash flow of $-32.56 Million could theoretically repay 0% of its total liabilities ($116.94 Million) in one year. See Mineralys Therapeutics, Inc. Common Stoc leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Mineralys Therapeutics, Inc. Common Stock (2020–2025)
Cash flow-to-debt ratio of Mineralys Therapeutics, Inc. Common Stock from 2020 to 2025. Historical debt coverage capacity for Mineralys Therapeutics, Inc. Common Stock across 6 annual periods. Also explore Mineralys Therapeutics, Inc. Common Stoc annual equity growth to track the company's year-over-year net asset growth rate.
Mineralys Therapeutics, Inc. Common Stock Cash Flow-to-Debt Ratio by Year (2020–2025)
Mineralys Therapeutics, Inc. Common Stock cash flow-to-debt ratio by year from 2020 to 2025. Year-by-year debt coverage analysis for Mineralys Therapeutics, Inc. Common Stock. For the full cash flow conversion analysis, see cash efficiency ratio of Mineralys Therapeutics, Inc. Common Stoc.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -9.42x | $-142.42 Million | $15.11 Million | ▲ +17.0% |
| 2024 | -11.36x | $-166.31 Million | $14.65 Million | ▼ -46.6% |
| 2023 | -7.74x | $-81.17 Million | $10.48 Million | ▼ -4318.1% |
| 2022 | -0.18x | $-29.22 Million | $166.71 Million | ▲ +59.0% |
| 2021 | -0.43x | $-14.56 Million | $34.05 Million | ▲ +11.8% |
| 2020 | -0.48x | $-2.46 Million | $5.08 Million | — |